Reverb Therapeutics has raised $17 million in funding to advance its Amplify•R™ platform, which engineers bispecific antibodies to regulate cytokine activity while minimizing toxicity. The round, led by Amplitude Ventures, included Myeloma Investment Fund, KdT Ventures, Finchley Healthcare Ventures, Seido Capital, and InBC Investment Corp.
Reverb’s lead candidate, AMP01, combines PD-1 targeting with IL-15 delivery to enhance T-cell function, demonstrating tumor reduction in preclinical studies. CEO David de Graaf, Ph.D., says the funds will support AMP01’s progression and further cytokine-based programs.
Want to know more? Check out the source code on Techcouver.